Facebook
X

Phone: (843) 449-1010 | 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572

Home
About Us
Staff
Current Trials
Patient Info
Testimonials
In The News
- In The News
Contact
Search
Menu Menu

Blog - Latest News

You are here: Home1 / In The News2 / Uncategorized3 / Pfizer and astellas announce positive top line results from phase 3 prosper...

CLICK HERE

September 14, 2017/in Uncategorized/by CURC

to view article

Share this entry

Share on Facebook
Share on X
Share on X
Share on WhatsApp
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

https://carolinaurologicresearchcenter.com/wp-content/uploads/9.14-Pfizer.jpg 250 300 CURC /wp-content/uploads/logo-1.png CURC2017-09-14 09:39:082017-09-14 09:40:45Pfizer and astellas announce positive top line results from phase 3 prosper trial of xtandi enzalutamide in patients with non metastatic castration resistant prostate cancer. With Dr. Neal Shore

Current Happenings

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?
Editorial Comment: Integrating Broad Panel Somatic and Germline Testing in Prostate Cancer Care
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology
Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572

Phone: (843) 839-1679
Fax: (843) 286-0119

Email:
info@curcmb.com

Directions

Recent Happenings

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?

Our Affiliates

Facebook
X

ESMO 2017: Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with...

Recombinant Adenovirus Interferon-α With Syn3 in BCG-Refractory or Relapsed...

Scroll to top

Contact

Recent Happenings

Our Affiliates